busulfan Search Results


busulfan  (MedChemExpress)
94
MedChemExpress busulfan
Busulfan, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/busulfan/product/MedChemExpress
Average 94 stars, based on 1 article reviews
busulfan - by Bioz Stars, 2026-04
94/100 stars
  Buy from Supplier
busulfan  (TargetMol)
93
TargetMol busulfan
Busulfan, supplied by TargetMol, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/busulfan/product/TargetMol
Average 93 stars, based on 1 article reviews
busulfan - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier
nsgs male mice  (Santa Cruz Biotechnology)
88
Santa Cruz Biotechnology nsgs male mice
Fig. 5. Therapeutic ASOs delivered by RBCEVs suppress tumor growth in vivo. a Outline of AML xenografting and ASO delivery in <t>NSGS</t> mice. b Representative bioluminescent images of NSGS mice implanted with MOLM13-luciferase-GFP cells followed by BCL2 ASO-loaded RBCEVs treatment. Pseudocolors indicate bioluminescent intensity (photon/second). <t>c</t> <t>Leukemia</t> progression in mice was quantified using the average bioluminescent signals following treatment with PBS (n = 5 mice), and RBCEVs loaded with NC ASO or BCL2 ASOs (n = 6 mice). d Percentage of GFP-positive leukemia cells in the bone marrow, liver, and spleen of mice treated with PBS, NC ASO-, or BCL2 ASO-loaded RBCEVs. e The average weight of the leukemia xenograft mice treated with PBS, NC ASO-, or BCL2 ASO-loaded RBCEVs. All bar graphs represent mean ± SEM. ns – not significant, * P < 0.05 and * * P < 0.01 determined by Student’s one-tailed t-test and two-way ANOVA with Tukey post-hoc test (c).
Nsgs Male Mice, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 88/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/nsgs male mice/product/Santa Cruz Biotechnology
Average 88 stars, based on 1 article reviews
nsgs male mice - by Bioz Stars, 2026-04
88/100 stars
  Buy from Supplier
nsg mice  (Selleck Chemicals)
94
Selleck Chemicals nsg mice
Fig. 5. Therapeutic ASOs delivered by RBCEVs suppress tumor growth in vivo. a Outline of AML xenografting and ASO delivery in <t>NSGS</t> mice. b Representative bioluminescent images of NSGS mice implanted with MOLM13-luciferase-GFP cells followed by BCL2 ASO-loaded RBCEVs treatment. Pseudocolors indicate bioluminescent intensity (photon/second). <t>c</t> <t>Leukemia</t> progression in mice was quantified using the average bioluminescent signals following treatment with PBS (n = 5 mice), and RBCEVs loaded with NC ASO or BCL2 ASOs (n = 6 mice). d Percentage of GFP-positive leukemia cells in the bone marrow, liver, and spleen of mice treated with PBS, NC ASO-, or BCL2 ASO-loaded RBCEVs. e The average weight of the leukemia xenograft mice treated with PBS, NC ASO-, or BCL2 ASO-loaded RBCEVs. All bar graphs represent mean ± SEM. ns – not significant, * P < 0.05 and * * P < 0.01 determined by Student’s one-tailed t-test and two-way ANOVA with Tukey post-hoc test (c).
Nsg Mice, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/nsg mice/product/Selleck Chemicals
Average 94 stars, based on 1 article reviews
nsg mice - by Bioz Stars, 2026-04
94/100 stars
  Buy from Supplier
busulfan  (LKT Laboratories)
90
LKT Laboratories busulfan
Fig. 5. Therapeutic ASOs delivered by RBCEVs suppress tumor growth in vivo. a Outline of AML xenografting and ASO delivery in <t>NSGS</t> mice. b Representative bioluminescent images of NSGS mice implanted with MOLM13-luciferase-GFP cells followed by BCL2 ASO-loaded RBCEVs treatment. Pseudocolors indicate bioluminescent intensity (photon/second). <t>c</t> <t>Leukemia</t> progression in mice was quantified using the average bioluminescent signals following treatment with PBS (n = 5 mice), and RBCEVs loaded with NC ASO or BCL2 ASOs (n = 6 mice). d Percentage of GFP-positive leukemia cells in the bone marrow, liver, and spleen of mice treated with PBS, NC ASO-, or BCL2 ASO-loaded RBCEVs. e The average weight of the leukemia xenograft mice treated with PBS, NC ASO-, or BCL2 ASO-loaded RBCEVs. All bar graphs represent mean ± SEM. ns – not significant, * P < 0.05 and * * P < 0.01 determined by Student’s one-tailed t-test and two-way ANOVA with Tukey post-hoc test (c).
Busulfan, supplied by LKT Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/busulfan/product/LKT Laboratories
Average 90 stars, based on 1 article reviews
busulfan - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
busulfan d8 bu d8 internal standard  (Santa Cruz Biotechnology)
94
Santa Cruz Biotechnology busulfan d8 bu d8 internal standard
Fig. 5. Therapeutic ASOs delivered by RBCEVs suppress tumor growth in vivo. a Outline of AML xenografting and ASO delivery in <t>NSGS</t> mice. b Representative bioluminescent images of NSGS mice implanted with MOLM13-luciferase-GFP cells followed by BCL2 ASO-loaded RBCEVs treatment. Pseudocolors indicate bioluminescent intensity (photon/second). <t>c</t> <t>Leukemia</t> progression in mice was quantified using the average bioluminescent signals following treatment with PBS (n = 5 mice), and RBCEVs loaded with NC ASO or BCL2 ASOs (n = 6 mice). d Percentage of GFP-positive leukemia cells in the bone marrow, liver, and spleen of mice treated with PBS, NC ASO-, or BCL2 ASO-loaded RBCEVs. e The average weight of the leukemia xenograft mice treated with PBS, NC ASO-, or BCL2 ASO-loaded RBCEVs. All bar graphs represent mean ± SEM. ns – not significant, * P < 0.05 and * * P < 0.01 determined by Student’s one-tailed t-test and two-way ANOVA with Tukey post-hoc test (c).
Busulfan D8 Bu D8 Internal Standard, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/busulfan d8 bu d8 internal standard/product/Santa Cruz Biotechnology
Average 94 stars, based on 1 article reviews
busulfan d8 bu d8 internal standard - by Bioz Stars, 2026-04
94/100 stars
  Buy from Supplier
bu busulfex  (Orphan Medical)
90
Orphan Medical bu busulfex
Fig. 5. Therapeutic ASOs delivered by RBCEVs suppress tumor growth in vivo. a Outline of AML xenografting and ASO delivery in <t>NSGS</t> mice. b Representative bioluminescent images of NSGS mice implanted with MOLM13-luciferase-GFP cells followed by BCL2 ASO-loaded RBCEVs treatment. Pseudocolors indicate bioluminescent intensity (photon/second). <t>c</t> <t>Leukemia</t> progression in mice was quantified using the average bioluminescent signals following treatment with PBS (n = 5 mice), and RBCEVs loaded with NC ASO or BCL2 ASOs (n = 6 mice). d Percentage of GFP-positive leukemia cells in the bone marrow, liver, and spleen of mice treated with PBS, NC ASO-, or BCL2 ASO-loaded RBCEVs. e The average weight of the leukemia xenograft mice treated with PBS, NC ASO-, or BCL2 ASO-loaded RBCEVs. All bar graphs represent mean ± SEM. ns – not significant, * P < 0.05 and * * P < 0.01 determined by Student’s one-tailed t-test and two-way ANOVA with Tukey post-hoc test (c).
Bu Busulfex, supplied by Orphan Medical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bu busulfex/product/Orphan Medical
Average 90 stars, based on 1 article reviews
bu busulfex - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
busulfan busilvex  (Pierre Fabre Group)
90
Pierre Fabre Group busulfan busilvex
Fig. 5. Therapeutic ASOs delivered by RBCEVs suppress tumor growth in vivo. a Outline of AML xenografting and ASO delivery in <t>NSGS</t> mice. b Representative bioluminescent images of NSGS mice implanted with MOLM13-luciferase-GFP cells followed by BCL2 ASO-loaded RBCEVs treatment. Pseudocolors indicate bioluminescent intensity (photon/second). <t>c</t> <t>Leukemia</t> progression in mice was quantified using the average bioluminescent signals following treatment with PBS (n = 5 mice), and RBCEVs loaded with NC ASO or BCL2 ASOs (n = 6 mice). d Percentage of GFP-positive leukemia cells in the bone marrow, liver, and spleen of mice treated with PBS, NC ASO-, or BCL2 ASO-loaded RBCEVs. e The average weight of the leukemia xenograft mice treated with PBS, NC ASO-, or BCL2 ASO-loaded RBCEVs. All bar graphs represent mean ± SEM. ns – not significant, * P < 0.05 and * * P < 0.01 determined by Student’s one-tailed t-test and two-way ANOVA with Tukey post-hoc test (c).
Busulfan Busilvex, supplied by Pierre Fabre Group, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/busulfan busilvex/product/Pierre Fabre Group
Average 90 stars, based on 1 article reviews
busulfan busilvex - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
oral busulfan myleran  (Glaxo Smith)
90
Glaxo Smith oral busulfan myleran
Fig. 5. Therapeutic ASOs delivered by RBCEVs suppress tumor growth in vivo. a Outline of AML xenografting and ASO delivery in <t>NSGS</t> mice. b Representative bioluminescent images of NSGS mice implanted with MOLM13-luciferase-GFP cells followed by BCL2 ASO-loaded RBCEVs treatment. Pseudocolors indicate bioluminescent intensity (photon/second). <t>c</t> <t>Leukemia</t> progression in mice was quantified using the average bioluminescent signals following treatment with PBS (n = 5 mice), and RBCEVs loaded with NC ASO or BCL2 ASOs (n = 6 mice). d Percentage of GFP-positive leukemia cells in the bone marrow, liver, and spleen of mice treated with PBS, NC ASO-, or BCL2 ASO-loaded RBCEVs. e The average weight of the leukemia xenograft mice treated with PBS, NC ASO-, or BCL2 ASO-loaded RBCEVs. All bar graphs represent mean ± SEM. ns – not significant, * P < 0.05 and * * P < 0.01 determined by Student’s one-tailed t-test and two-way ANOVA with Tukey post-hoc test (c).
Oral Busulfan Myleran, supplied by Glaxo Smith, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/oral busulfan myleran/product/Glaxo Smith
Average 90 stars, based on 1 article reviews
oral busulfan myleran - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
busulfan busulfex  (PDL BioPharma)
90
PDL BioPharma busulfan busulfex
Fig. 5. Therapeutic ASOs delivered by RBCEVs suppress tumor growth in vivo. a Outline of AML xenografting and ASO delivery in <t>NSGS</t> mice. b Representative bioluminescent images of NSGS mice implanted with MOLM13-luciferase-GFP cells followed by BCL2 ASO-loaded RBCEVs treatment. Pseudocolors indicate bioluminescent intensity (photon/second). <t>c</t> <t>Leukemia</t> progression in mice was quantified using the average bioluminescent signals following treatment with PBS (n = 5 mice), and RBCEVs loaded with NC ASO or BCL2 ASOs (n = 6 mice). d Percentage of GFP-positive leukemia cells in the bone marrow, liver, and spleen of mice treated with PBS, NC ASO-, or BCL2 ASO-loaded RBCEVs. e The average weight of the leukemia xenograft mice treated with PBS, NC ASO-, or BCL2 ASO-loaded RBCEVs. All bar graphs represent mean ± SEM. ns – not significant, * P < 0.05 and * * P < 0.01 determined by Student’s one-tailed t-test and two-way ANOVA with Tukey post-hoc test (c).
Busulfan Busulfex, supplied by PDL BioPharma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/busulfan busulfex/product/PDL BioPharma
Average 90 stars, based on 1 article reviews
busulfan busulfex - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
intrathecal spartaject busulfan  (SuperGen Inc)
90
SuperGen Inc intrathecal spartaject busulfan
Fig. 5. Therapeutic ASOs delivered by RBCEVs suppress tumor growth in vivo. a Outline of AML xenografting and ASO delivery in <t>NSGS</t> mice. b Representative bioluminescent images of NSGS mice implanted with MOLM13-luciferase-GFP cells followed by BCL2 ASO-loaded RBCEVs treatment. Pseudocolors indicate bioluminescent intensity (photon/second). <t>c</t> <t>Leukemia</t> progression in mice was quantified using the average bioluminescent signals following treatment with PBS (n = 5 mice), and RBCEVs loaded with NC ASO or BCL2 ASOs (n = 6 mice). d Percentage of GFP-positive leukemia cells in the bone marrow, liver, and spleen of mice treated with PBS, NC ASO-, or BCL2 ASO-loaded RBCEVs. e The average weight of the leukemia xenograft mice treated with PBS, NC ASO-, or BCL2 ASO-loaded RBCEVs. All bar graphs represent mean ± SEM. ns – not significant, * P < 0.05 and * * P < 0.01 determined by Student’s one-tailed t-test and two-way ANOVA with Tukey post-hoc test (c).
Intrathecal Spartaject Busulfan, supplied by SuperGen Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/intrathecal spartaject busulfan/product/SuperGen Inc
Average 90 stars, based on 1 article reviews
intrathecal spartaject busulfan - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
busulfan liquid orphan medical  (Orphan Medical)
90
Orphan Medical busulfan liquid orphan medical
Fig. 5. Therapeutic ASOs delivered by RBCEVs suppress tumor growth in vivo. a Outline of AML xenografting and ASO delivery in <t>NSGS</t> mice. b Representative bioluminescent images of NSGS mice implanted with MOLM13-luciferase-GFP cells followed by BCL2 ASO-loaded RBCEVs treatment. Pseudocolors indicate bioluminescent intensity (photon/second). <t>c</t> <t>Leukemia</t> progression in mice was quantified using the average bioluminescent signals following treatment with PBS (n = 5 mice), and RBCEVs loaded with NC ASO or BCL2 ASOs (n = 6 mice). d Percentage of GFP-positive leukemia cells in the bone marrow, liver, and spleen of mice treated with PBS, NC ASO-, or BCL2 ASO-loaded RBCEVs. e The average weight of the leukemia xenograft mice treated with PBS, NC ASO-, or BCL2 ASO-loaded RBCEVs. All bar graphs represent mean ± SEM. ns – not significant, * P < 0.05 and * * P < 0.01 determined by Student’s one-tailed t-test and two-way ANOVA with Tukey post-hoc test (c).
Busulfan Liquid Orphan Medical, supplied by Orphan Medical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/busulfan liquid orphan medical/product/Orphan Medical
Average 90 stars, based on 1 article reviews
busulfan liquid orphan medical - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

Image Search Results


Fig. 5. Therapeutic ASOs delivered by RBCEVs suppress tumor growth in vivo. a Outline of AML xenografting and ASO delivery in NSGS mice. b Representative bioluminescent images of NSGS mice implanted with MOLM13-luciferase-GFP cells followed by BCL2 ASO-loaded RBCEVs treatment. Pseudocolors indicate bioluminescent intensity (photon/second). c Leukemia progression in mice was quantified using the average bioluminescent signals following treatment with PBS (n = 5 mice), and RBCEVs loaded with NC ASO or BCL2 ASOs (n = 6 mice). d Percentage of GFP-positive leukemia cells in the bone marrow, liver, and spleen of mice treated with PBS, NC ASO-, or BCL2 ASO-loaded RBCEVs. e The average weight of the leukemia xenograft mice treated with PBS, NC ASO-, or BCL2 ASO-loaded RBCEVs. All bar graphs represent mean ± SEM. ns – not significant, * P < 0.05 and * * P < 0.01 determined by Student’s one-tailed t-test and two-way ANOVA with Tukey post-hoc test (c).

Journal: Pharmacological research

Article Title: Endosomal escape of nucleic acids from extracellular vesicles mediates functional therapeutic delivery.

doi: 10.1016/j.phrs.2023.106665

Figure Lengend Snippet: Fig. 5. Therapeutic ASOs delivered by RBCEVs suppress tumor growth in vivo. a Outline of AML xenografting and ASO delivery in NSGS mice. b Representative bioluminescent images of NSGS mice implanted with MOLM13-luciferase-GFP cells followed by BCL2 ASO-loaded RBCEVs treatment. Pseudocolors indicate bioluminescent intensity (photon/second). c Leukemia progression in mice was quantified using the average bioluminescent signals following treatment with PBS (n = 5 mice), and RBCEVs loaded with NC ASO or BCL2 ASOs (n = 6 mice). d Percentage of GFP-positive leukemia cells in the bone marrow, liver, and spleen of mice treated with PBS, NC ASO-, or BCL2 ASO-loaded RBCEVs. e The average weight of the leukemia xenograft mice treated with PBS, NC ASO-, or BCL2 ASO-loaded RBCEVs. All bar graphs represent mean ± SEM. ns – not significant, * P < 0.05 and * * P < 0.01 determined by Student’s one-tailed t-test and two-way ANOVA with Tukey post-hoc test (c).

Article Snippet: To generate xenografted murine model for acute myeloid leukemia, NSGS male mice of 8–9 weeks old (24.6 ± 0.65 g) were pre-conditioned with Busulfan (Santa Cruz, 20 mg/kg) by tail vein injection.

Techniques: In Vivo, Luciferase, One-tailed Test